MBX Biosciences, Inc. (MBX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$61.72+0.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MBX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -21.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MBX — litigation filed
Dated 2026-08-27
Other Events. On August 27, 2026, the Company announced the dosing of the first patient in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP). A summary of the trial design is as follows: Phase 3 oPTimize trial design The Phase 3 oPTimize trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-weekly canvuparatide in adults with chronic HP, f…
Why it matters: Starting the Phase 3 trial is key for canvuparatide. It aims to treat chronic hypoparathyroidism.
Supportive ifThe first patient is dosed in the Phase 3 trial of canvuparatide in Q3 2026.
Worry ifThe trial does not start as planned or faces significant delays.
Why it matters: Preclinical data will show if MBX 5765 could be a new treatment for obesity.
Supportive ifMBX 5765 preclinical data will be presented at a scientific meeting in Q4 2026.
Worry ifNo data is presented or results are disappointing.
Why it matters: Expanding the obesity portfolio can boost growth and market presence. It shows commitment to this area.
Supportive ifThey will share new options for the obesity treatments.
Worry ifNo new options were shared for the obesity treatments.
Why it matters: Having enough cash is important for funding trials and operations.
Supportive ifCash and investments remain at or above $418.6 million as of Q3 2026.
Worry ifCash reserves are much lower than what management thought.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$264 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $752 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,760 loss on $10,000 · 37.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The data will show if canvuparatide is effective. Positive results could boost confidence in the drug's potential.
Supportive ifData from the past year shows a responder rate over 63% in patients treated with canvuparatide.
Worry ifLess than 63% of patients treated with canvuparatide respond.
Why it matters: Data from this trial will show if MBX 4291 can support once-monthly dosing for obesity.
Watch forPositive results from the 12-week MAD (Part C) of the Phase 1 trial for MBX 4291.
Also watch forData shows that MBX 4291 does not work well or is hard to tolerate.
Why it matters: Cash reserves can impact MBX's ability to pay for trials. It also affects operations.
Worry ifCash reserves remain stable or increase from $418.6 million.
Less concerning ifCash reserves drop a lot or go below the current level.
Why it matters: Keeping enough cash until 2029 is key for operations. Changes could affect financial health.
Worry ifAbout $373.7 million in cash and equivalents was confirmed during the Q2 earnings call.
Less concerning ifCash and equivalents were lower than expected. Look for big changes in cash guidance.